# Arrowhead Pharmaceuticals (ARWR) — Analyst Forecast

ARWR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/arwr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 15 | 1 | 0 | 16 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $74.00 | $109.00 | $126.00 | 10 |

Last price $58.50 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Oct 15, 2026 | Chardan Capital | Maintained | Buy | $115.00 |
| Oct 15, 2026 | UBS | Initiated Coverage | Buy | $109.00 |
| Sep 24, 2026 | Goldman Sachs | Maintained | Neutral | $74.00 |
| Sep 8, 2026 | Citigroup | Initiated Coverage | Buy | $108.00 |
| Sep 1, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Aug 31, 2026 | RBC Capital | Maintained | Outperform | $100.00 |
| Aug 31, 2026 | Chardan Capital | Maintained | Buy | $115.00 |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Jul 30, 2026 | B. Riley Securities | Maintained | Buy | $123.00 |
| Jul 27, 2026 | HC Wainwright & Co. | Maintained | Buy | $115.00 |
| Jul 23, 2026 | Piper Sandler | Maintained | Overweight | $126.00 |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | $120.00 |
| Jul 22, 2026 | Chardan Capital | Maintained | Buy | $115.00 |
| Jul 17, 2026 | JP Morgan | Maintained | Overweight | $95.00 |
| Jul 14, 2026 | Stifel | Initiated Coverage | Buy | $98.00 |
| Jul 1, 2026 | HC Wainwright & Co. | Maintained | Buy | $100.00 |
| Jun 30, 2026 | Chardan Capital | Maintained | Buy | $90.00 |
| Jun 17, 2026 | Leerink Partners | Maintained | Market Perform | $72.00 |
| May 13, 2026 | Bernstein | Maintained | Market Perform | $46.00 |

## Frequently Asked Questions

### What is the price target for ARWR stock?

The average 12-month analyst price target for Arrowhead Pharmaceuticals (ARWR) is $109.00, with a high estimate of $126.00 and a low of $74.00, across 10 analysts.

### Is ARWR a buy, sell, or hold?

Analysts covering Arrowhead Pharmaceuticals currently average a Buy rating: 15 buy, 1 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ARWR?

The average price target of $109.00 implies 86.32% upside from the last price of $58.50.

### What is the latest analyst rating on ARWR?

On Oct 15, 2026, HC Wainwright & Co. maintained Arrowhead Pharmaceuticals at Buy with a price target of $120.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).